Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Raymond James Maintains Outperform on PubMatic, Lowers Price Target to $17

Raymond James analyst Andrew Marok maintains PubMatic (NASDAQ:PUBM) with a Outperform and lowers the price target from $18 to $17.

byBenzinga Newsdesk

March 1, 2023

1 minute read

Raymond James analyst Andrew Marok maintains PubMatic (NASDAQ:PUBM) with a Outperform and lowers the price target from $18 to $17.

Needham Maintains Buy on Revance Therapeutics, Lowers Price Target to $25

By Benzinga Newsdesk

Today, 11:29 PM

Needham analyst Serge Belanger maintains Revance Therapeutics (NASDAQ:RVNC) with a Buy and lowers the price target from $45 to $25.

RVNC

Canada PM Trudeu To Invoke Emergencies Act To Give Government Extra Powers To Deal With Protests

By Benzinga Newsdesk

Today, 11:29 PM

-CBC News

EWC

CORRECTION: DA Davidson Maintains Buy on Asana, Raises Price Target to $21 – Rating Change Updated

By Benzinga Newsdesk

Today, 11:29 PM

CORRECTION: DA Davidson analyst Robert Simmons maintains Asana (NYSE:ASAN) with a Buy and raises the price target from $18 to $21, rating change updated.

ASAN

‘A Near Insurmountable Climb’: Pinterest Analysts React To Q4 Earnings Beat

By Wayne Duggan

Today, 11:29 PM

Pinterest Inc (NYSE: PINS) shares traded higher by 8.7% on Friday after the company reported a fourth-quarter earnings beat on Thursday afternoon.

PINS

Raymond James Maintains Outperform on PubMatic, Lowers Price Target to $17

Related Posts

Needham Maintains Buy on Revance Therapeutics, Lowers Price Target to $25

Canada PM Trudeu To Invoke Emergencies Act To Give Government Extra Powers To Deal With Protests

CORRECTION: DA Davidson Maintains Buy on Asana, Raises Price Target to $21 – Rating Change Updated

‘A Near Insurmountable Climb’: Pinterest Analysts React To Q4 Earnings Beat